Highlights

  • Additional $400,000 cornerstone investment increases total placement to approximately $1.3 million.
  • Placement completed at $0.02 per share, with two unlisted options (exercise price $0.04, two-year expiry) attached to each share.
  • Funds will support development of reformulated pharmaceutical candidates targeting large global markets, including sexual health and cardiovascular therapies.

EVE Health Group Limited (ASX:EVE) has updated its March 2026 placement, confirming an additional $400,000 commitment from a cornerstone investor, lifting total funds raised to approximately $1.3 million. The placement was completed at $0.02 per share, with investors receiving two unlisted options per share exercisable at $0.04 and expiring in two years. The cornerstone investor brings pharmaceutical development and commercialisation expertise, reinforcing confidence in EVE’s strategy. Funds will support the advancement of reformulated drug candidates, proprietary drug delivery technologies, and related intellectual property and regulatory activities across key global therapeutic markets.

Placement Update

The additional cornerstone investment was made on the same terms as the original placement announced on 13 March 2026. The strategic investor has experience in pharmaceutical development, regulatory pathways, and global commercialisation, aligning with EVE’s long-term objectives. Red Leaf Securities Pty Ltd acted as Lead Manager and Bookrunner for the transaction. The capital raising structure included attaching options, providing potential future funding flexibility while maintaining alignment between investors and the Company’s growth strategy. The strengthened funding position supports continued execution of development milestones.

Strategy and Use of Funds

EVE is focused on reformulating established pharmaceutical compounds approaching patent expiry using proprietary drug delivery and solubilisation technologies. The approach aims to improve bioavailability, onset of action, and patient convenience while leveraging existing safety profiles. The Company is progressing programs in sexual health and cardiovascular therapies, targeting markets estimated to exceed US$30 billion annually. Proceeds from the placement will advance product development, technology platforms, intellectual property protection, and regulatory activities, supporting potential licensing or commercial partnerships with established pharmaceutical companies.

FAQs

  1. How much capital did EVE raise in this placement?

EVE raised approximately $1.3 million, including an additional $400,000 commitment from a cornerstone investor.

  1. What were the terms of the placement?

Shares were issued at $0.02 each, with investors receiving two unlisted options per share, exercisable at $0.04 and expiring in two years.

  1. How will the funds be used?

The funds will support product development, advancement of drug delivery technologies, and ongoing intellectual property and regulatory activities.